Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inge Dierynck

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
AIDS Research and Human Retroviruses|May 29, 2010
Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study dataJohan Vingerhoets, Hilde Azijn, Lotke Tambuyzer, et al.
Antimicrobial Agents and Chemotherapy|September 8, 2011
TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitorsInge Dierynck, Herwig Van Marck, Marcia Van Ginderen, et al.
AIDS (London, England)|June 3, 2009
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAnthony M Mills, Mark Nelson, Dushyantha Jayaweera, et al.
AIDS (London, England)|May 29, 2009
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patientsSandra De Meyer, Erkki Lathouwers, Inge Dierynck, et al.
Hepatology (Baltimore, Md.)|July 19, 2012
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trialSandra De Meyer, Inge Dierynck, Anne Ghys, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2013
Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patientsHans-Jürgen Stellbrink, Keikawus Arastéh, Dirk Schürmann, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 28, 2014
Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infectionGaston Picchio, Sandra De Meyer, Inge Dierynck, et al.
Plos Computational Biology|August 8, 2014
Modeling viral evolutionary dynamics after telaprevir-based treatmentEric L Haseltine, Sandra De Meyer, Inge Dierynck, et al.
Journal of Medicinal Chemistry|March 18, 2005
Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integraseWim G Verschueren, Inge Dierynck, Katie I E Amssoms, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2013
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trialsJames C Sullivan, Sandra De Meyer, Doug J Bartels, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
AIDS Research and Human Retroviruses|May 29, 2010
Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study dataJohan Vingerhoets, Hilde Azijn, Lotke Tambuyzer, et al.
Antimicrobial Agents and Chemotherapy|September 8, 2011
TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitorsInge Dierynck, Herwig Van Marck, Marcia Van Ginderen, et al.
AIDS (London, England)|June 3, 2009
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAnthony M Mills, Mark Nelson, Dushyantha Jayaweera, et al.
AIDS (London, England)|May 29, 2009
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patientsSandra De Meyer, Erkki Lathouwers, Inge Dierynck, et al.
Hepatology (Baltimore, Md.)|July 19, 2012
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trialSandra De Meyer, Inge Dierynck, Anne Ghys, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2013
Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patientsHans-Jürgen Stellbrink, Keikawus Arastéh, Dirk Schürmann, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 28, 2014
Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infectionGaston Picchio, Sandra De Meyer, Inge Dierynck, et al.
Plos Computational Biology|August 8, 2014
Modeling viral evolutionary dynamics after telaprevir-based treatmentEric L Haseltine, Sandra De Meyer, Inge Dierynck, et al.
Journal of Medicinal Chemistry|March 18, 2005
Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integraseWim G Verschueren, Inge Dierynck, Katie I E Amssoms, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2013
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trialsJames C Sullivan, Sandra De Meyer, Doug J Bartels, et al.
Pageof 3